Ridding the human body of HIV

Dec 02, 2010 By Erin White

A new Northwestern Medicine study will undertake a bold new protocol to completely eradicate latent HIV cells that current drugs don't affect. Participants, with diagnosed HIV, in the experimental group will be given an investigational HIV vaccine that actually wakes up dormant cells at the same time regular HIV-drug therapy is aimed at extinguishing the activated cells.

“If we can effectively decrease the reservoir then we can think about curing ," said Robert Murphy, M.D., founding director of Northwestern University Feinberg School of Medicine’s Center for Global Health and an infectious disease physician at Northwestern Memorial Hospital.

Many people with HIV are living with nearly undetectable levels of the virus in their blood, but they can’t entirely clear HIV out of their bodies with the current treatment regimens. Dormant HIV cells linger, hiding in the body and resisting the powerful benefits of anti-HIV drugs. Through the study, called EraMune 02, researchers at Feinberg’s Center for Global Health plan to activate dormant HIV cells, fight them off and kill the virus.

The first participant in the study was enrolled at Northwestern Medicine this week. The study will ultimately enroll and study 28 already HIV-infected participants in Chicago, New York and San Francisco for more than one year. A similar study, EraMune 01, also is taking place in Europe and includes participants from France, Spain, Italy and England.

“There is a reservoir of dormant, latently infected cells that current drugs don’t affect, and we think we now have drugs available that can actually attack the virus in the reservoir,” said Murphy, the principal investigator of the study and John Philip Phair professor of infectious diseases at Feinberg.

All participants will be given intensified doses of anti-HIV drugs for two months. Intensified drug therapy can suppress the amount of HIV in the blood to very low levels. Then participants will be randomly assigned (50/50) to either a control or an experimental group. In addition to the intensified HIV therapy, the experimental group will receive an investigational . In previous studies this vaccine has been shown to activate latently infected HIV cells.

“If you activate those cells in the presence of giving regular HIV-drug therapy, which would control and fight the virus, you might be able to extinguish the reservoir,” Murphy said.

After the treatment phase researchers will follow the participants for one year. They will study the white blood cells of the participants and measure the amount of HIV in the integrated DNA of the cells. This is the first in a series of studies that will examine the effect the intensified treatment and the vaccine have on the reservoir of latent HIV cells, Murphy said.

“We think it is a step in the right direction to find the immunologic agent that will eradicate the reservoir,“ Murphy said.

Explore further: Withdrawal from the evolutionary race

add to favorites email to friend print save as pdf

Related Stories

Exhausted B cells fail to fight HIV

Jul 14, 2008

HIV tires out the cells that produce virus-fighting proteins known as antibodies, according to a human study that will be published online July 14 in the Journal of Experimental Medicine.

Waking up dormant HIV

Mar 16, 2009

HAART (highly active anti-retroviral therapy) has emerged as an extremely effective HIV treatment that keeps virus levels almost undetectable; however, HAART can never truly eradicate the virus as some HIV always remains ...

Exhausted B cells hamper immune response to HIV

Jul 14, 2008

Recent studies have shown that HIV causes a vigorous and prolonged immune response that eventually leads to the exhaustion of key immune system cells--CD4+ and CD8+ T-cells--that target HIV. These tired cells become less ...

How HIV vaccine might have increased odds of infection

Nov 03, 2008

In September 2007, a phase II HIV-1 vaccine trial was abruptly halted when researchers found that the vaccine may have promoted, rather than prevented, HIV infection. A new study by a team of researchers at the Montpellier ...

Bone marrow can harbor HIV-infected cells (w/ Video)

Mar 07, 2010

University of Michigan scientists have identified a new reservoir for hidden HIV-infected cells that can serve as a factory for new infections. The findings, which appear online March 7 in Nature Medicine, indicate a new ...

A cure for HIV could be all in the 'mix'

Aug 18, 2010

Current HIV treatments do not eradicate HIV from host cells but rather inhibit virus replication and delay the onset of AIDS. However, a new research published in BioMed Central's open access journal, AIDS Research & Therapy descri ...

Recommended for you

Condoms 'too small' for Uganda men

15 hours ago

Ugandan MPs have been inundated with complaints that many condoms on sale in the east African nation are too small, warning the problem is a blow to the fight against AIDS.

Withdrawal from the evolutionary race

Sep 18, 2014

In some HIV sufferers, the immune system does not fight off the immune deficiency virus. Instead, the body tolerates the pathogen. A research team headed by ETH Zurich has now determined how strongly patients ...

The genetics of coping with HIV

Sep 16, 2014

We respond to infections in two fundamental ways. One, which has been the subject of intensive research over the years, is "resistance," where the body attacks the invading pathogen and reduces its numbers. Another, which ...

User comments : 0